2024-11-19 17:19:43
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers
Health/ 2023-07-22
CARsgen Therapeutics Receives Orphan Med...

SHANGHAI,March 1,2021-- CARsgen Therapeutics Holdings Limited,a clinical-stage biopharmaceutical company,today announced that the European C...

Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
Health/ 2023-07-22
Merck Builds on Leadership in Head and N...

- Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated loca...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release